ArticleCurrent microbiology2026
Synergistic Effects of Clove Essential Oil, Eugenol, Isoeugenol Combined with Meropenem against MRSA, Acinetobacter Baumannii, Bacillus spp in Vitro.
Article in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibiotic resistance, particularly multidrug resistance (MDR), remains a major global health threat. Combining natural products with conventional antibiotics, such as meropenem (MRP), offers a promising approach to enhance antibacterial efficacy. Syzygium aromaticum (clove) (SAE) is rich in bioactive compounds, notably eugenol (EU) and isoeugenol (IEU), yet studies on their synergy with MRP against MRSA, Acinetobacter baumannii, and Bacillus spp. are limited. This study evaluated the antibacterial activity of SAE, EU, and IEU, alone and in combination with MRP, using MICs, FICI, isobolograms, and dose reduction index (DRI) of MRP. The SAE-MRP combination showed strong synergy against MRSA (DRI = 16) and Bacillus spp. (DRI = 33), with moderate synergy against A. baumannii (DRI = 4). EU-MRP showed the highest DRI against Bacillus spp. (33), followed by A. baumannii (8) and MRSA (4). IEU-MRP produced weaker effects, from additive activity against MRSA (DRI = 2) to synergy against Bacillus spp. (DRI = 8). These results highlight the potential of clove-derived compounds to enhance MRP efficacy, reduce antibiotic dosages, and support strategies to combat multidrug-resistant infections.
Indexed as
Identifiers
42470444What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.